Large pharma companies at FoG London 2027
Jan 27–28, 2027 London, UK ~8.3k attendees Website
11 large pharma companies are at FoG London 2027 — 17 presentations on the program and 1 with a booth in the exhibit hall. Most represented: GSK (5 on the program), AstraZeneca (5 on the program), UCB (3 on the program). 5 of them have their own page in this guide. As of Oct 29, 2026.
Topic
Top represented
Showing 1–11 of 11 organizations
| Organization | FoG London 2027 Attendance |
|---|---|
GSK London, UK | |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, oncology and immunology. | Talk Wed Jan 27 14:30–15:00 Making Biobank Data Useful for Drug Discovery How genetic data from large biobanks can point to promising drug targets and strengthen the evidence behind clinical development. Talk Wed Jan 27 14:30–15:00 Protein AI Models for Drug Discovery How AI models trained on protein sequences and structures could help explain disease and find drug targets. Talk Wed Jan 27 16:30–17:00 Data Science Opportunities in Oncology Discovery & Translation How combining genomic data, gene-disruption experiments and real-world patient records can link cancer drug targets to mechanisms and patient groups. Panel Wed Jan 27 17:30–18:00 Using High Dimensional Multi-Omic Data in Drug Discovery & Translational Research How combining several layers of molecular data can reveal drug targets and biomarkers, and what slows their path to the clinic. Panel Thu Jan 28 11:30–12:00 Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error? Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured. |
AstraZeneca Cambridge, UK | |
Global biopharmaceutical company with medicines in oncology, rare disease, cardiovascular, renal, respiratory and immunology. | Panel Wed Jan 27 17:30–18:00 Choosing the Right Sequencing Technology: Short Reads, Long Reads & Beyond How researchers weigh short-read and long-read sequencing on accuracy, resolution, throughput and cost, and when to combine them. Talk Wed Jan 27 17:30–18:00 From Human IN the Loop to Human ON the Loop Why scientists should help build AI tools from the start, and why keeping them reliable needs ongoing scientific oversight. Also |
UCB Brussels, Belgium | |
Belgian biopharmaceutical company developing medicines for neurology and immunology conditions. | Panel Thu Jan 28 11:30–12:00 Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error? Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured. Talk Thu Jan 28 16:10–16:40 Synthetic Data in Clinical Development: Enabling the Next Generation of Scientific Evidence How industry and regulators are setting rules for using synthetic, computer-generated data in drug development, from trial design to hard-to-study patient groups. Also |
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company focused on diabetes, obesity and other serious chronic diseases. | Talk Thu Jan 28 12:30–13:00 Session (details to come) How biology-led AI could turn many kinds of data into evidence strong enough to choose and prioritise drug targets early in research. Talk Thu Jan 28 15:10–15:40 Teaching AI to Understand Biology: From Cellular Perturbations to Intelligent Drug Discovery Whether AI models, including large language models, can predict cell responses to drugs, reason about biology and run bioinformatics tasks reliably. |
Alexion, AstraZeneca Rare Disease Boston, MA | |
AstraZeneca's rare disease unit, developing and selling medicines for rare conditions, including complement-inhibitor therapies. | Panel Wed Jan 27 12:30–13:00 Designing the Next Generation of Rare Disease Therapies: From Advanced Genomics to AI-Enabled Therapeutic Innovation How better knowledge of disease genetics and AI could shape the design of more precise, personalised treatments for rare diseases. |
Bayer Leverkusen, Germany | |
Life science group with pharmaceuticals, consumer health and crop science divisions, including cell and gene therapy programmes. | Panel Wed Jan 27 17:30–18:00 How Can We Bridge the Gap from Discovery to GMP Manufacturing? When and how cell and gene therapy developers should plan manufacturing and regulation so a lab process can scale without losing quality. |
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned pharmaceutical company developing human and animal health medicines. | Talk Thu Jan 28 16:40–17:10 Multimodal Identification of Disease Segments How machine learning on large blood protein datasets can sort patients into disease subtypes that standard diagnostic tests miss. |
Ipsen Boulogne-Billancourt, France | |
French biopharmaceutical company with marketed medicines in oncology, rare disease and neuroscience. | Panel Thu Jan 28 11:30–12:00 Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error? Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured. |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company with medicines in oncology, cardiovascular, immunology and neuroscience, including cell and gene therapies. | Talk Wed Jan 27 15:30–16:00 Applying AI for Oncology Drug Target Identification & Prioritisation How AI and single-cell, spatial and other molecular data can find and rank new cancer drug targets worth testing in the lab. |
Servier Suresnes, France | |
French pharmaceutical group governed by a foundation, developing medicines in oncology, cardiometabolic and other diseases. | Talk Wed Jan 27 12:30–13:00 Leveraging Genomic Sequence-to-Function Language Models for the Design of Antisense Oligonucleotides How AI models that predict what a DNA sequence does could help design antisense oligonucleotides, with early tests reproducing a known drug's effect. |
Octapharma Lachen, Switzerland | |
Privately owned Swiss maker of human protein medicines derived from plasma and human cell lines. | Booth Exhibiting at Booth 13 |
Find buyers from large pharma companies
Tell us what you sell and we’ll find the people at these large pharma companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse FoG London 2027 by
Organization type
Topic
- Genomic medicine & rare disease 54
- Cancer genomics & diagnostics 31
- AI in drug discovery & diagnostics 43
- Biodata & bioinformatics 33
- Single-cell genomics 24
- Spatial biology 19
- Multi-omics & proteomics 31
- Epigenetics & translational omics 16
- Pharmacogenomics & patient stratification 16
- Women’s and children’s health 13
- Cell & gene therapy 18
- Microbiome & pathogen genomics 17
- Plant & agricultural genomics 13
- Population & social genomics 23
Exhibit hall
Everyone
Not affiliated with or endorsed by Front Line Genomics or the Festival of Genomics. Submit a correction